Evidence map›Paper›PMID 35559682›Full record

ArticleScience advances2022

FasL microgels induce immune acceptance of islet allografts in nonhuman primates.

Ji Lei, María M Coronel, Esma S Yolcu, Hongping Deng, Orlando Grimany-Nuno, Michael D Hunckler, Vahap Ulker, Zhihong Yang, Kang M Lee, Alexander Zhang and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Engineering hypoimmune stem cell-derived beta cells.Stem cell research & therapy · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  15. Unlocking Transplant Tolerance with Biomaterials.Advanced healthcare materials · 2025
    Review
  16. Review
  17. Allogeneic Islet Transplantation: Chronicle of a Death Foretold?Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Ji LeiCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7704-2370
María M CoronelWoodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0001-9661-7221
Esma S YolcuDepartments of Child Health and Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, MO, USA.ORCID 0000-0002-4312-8798
Hongping DengCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9752-8965
Orlando Grimany-NunoDepartment of Microbiology and Immunology, Institute for Cellular Therapeutics, University of Louisville, Louisville, KY, USA.
Michael D HuncklerWoodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0002-4385-7667
Vahap UlkerDepartments of Child Health and Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, MO, USA.ORCID 0000-0002-8876-2119
Zhihong YangCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kang M LeeCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alexander ZhangCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4002-5192
Hao LuoDepartment of General Surgery, General Hospital of Western Theater Command, Chengdu, China.
Cole W PetersCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Zhongliang ZouCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tao ChenCellular Therapy Department, Xiang'an Hospital, Xiamen University Medical School, Xiamen, China.
Zhenjuan WangCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Colleen S McCoyDivision of Comparative Medicine, Massachusetts Institute of Technology, Boston, MA, USA.ORCID 0000-0002-8995-9394
Ivy A RosalesCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0621-3202
James F MarkmannCenter for Transplantation Science, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2762-6535
Haval ShirwanDepartments of Child Health and Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, MO, USA.ORCID 0000-0002-1657-9470
Andrés J GarcíaWoodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0001-6602-2518
Harvard University · USGeorgia Institute of Technology · USUniversity of Louisville · USMassachusetts Institute of Technology · USUniversity of Missouri Health System · USXiamen University · CN

Funding

BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATIONR01DK128840 · NIDDK · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J, SHIRWAN, HAVAL · 2021 to 2025
$2.1M
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet graftsU01AI132817 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI GARCIA, ANDRES J, SHIRWAN, HAVAL · 2017 to 2021
$2.0M
NIAID NIH HHS U01 AI132817NIDDK NIH HHS R01 DK128840
6 · The paper itself

Abstract

Islet transplantation to treat insulin-dependent diabetes is greatly limited by the need for maintenance immunosuppression. We report a strategy through which cotransplantation of allogeneic islets and streptavidin (SA)-FasL-presenting microgels to the omentum under transient rapamycin monotherapy resulted in robust glycemic control, sustained C-peptide levels, and graft survival in diabetic nonhuman primates for >6 months. Surgical extraction of the graft resulted in prompt hyperglycemia. In contrast, animals receiving microgels without SA-FasL under the same rapamycin regimen rejected islet grafts acutely. Graft survival was associated with increased number of FoxP3

Indexed as

Diabetes Mellitus, Type 1Islets of Langerhans TransplantationMicrogelsAllograftsAnimalsPrimatesSirolimusStreptavidinMicrogelsSirolimusStreptavidin

Identifiers

PMID35559682
PMCPMC9106299
OpenAlexW4280566781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.